Literature DB >> 20208478

p53 expression in tumor-stromal fibroblasts forming and not forming fibrotic foci in invasive ductal carcinoma of the breast.

Takahiro Hasebe1, Motoki Iwasaki, Sadako Akashi-Tanaka, Takashi Hojo, Tatsuhiro Shibata, Yuko Sasajima, Takayuki Kinoshita, Hitoshi Tsuda.   

Abstract

The purpose of this study was to determine whether p53 protein expression in tumor-stromal fibroblasts forming fibrotic foci is a significant outcome predictor, similar to p53 protein expression in tumor-stromal fibroblasts not forming fibrotic foci, and whether the combined assessment of p53 expression in tumor-stromal fibroblasts forming and not forming fibrotic foci served as an important outcome predictor among 1039 patients with invasive ductal carcinoma of the breast. We analyzed the outcome predictive power of the Allred score risk classification for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci using multivariate analyses with well-known clinicopathological factors. The Allred score risk classifications for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci were superior to the Allred scores for p53 in tumor-stromal fibroblasts not forming fibrotic foci alone for accurately predicting the tumor-related death of patients with invasive ductal carcinoma when examined using multivariate analyses. The Allred score risk classification for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci significantly increased the hazard rates for tumor recurrence and tumor-related death independent of the UICC pTNM stage in the multivariate analyses. These results indicated that the Allred score risk classification based on the combined assessment of p53 expression in tumor-stromal fibroblasts forming and not forming fibrotic foci is a very useful outcome predictor among patients with invasive ductal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20208478     DOI: 10.1038/modpathol.2010.47

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  5 in total

1.  p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).

Authors:  Jonathan F Lara; Ann D Thor; Lynn G Dressler; Gloria Broadwater; Ira J Bleiweiss; Susan Edgerton; David Cowan; Lori J Goldstein; Silvana Martino; James N Ingle; I Craig Henderson; Larry Norton; Eric P Winer; Clifford A Hudis; Matthew J Ellis; Donald A Berry; Daniel F Hayes
Journal:  Clin Cancer Res       Date:  2011-06-21       Impact factor: 12.531

2.  Differential expression of senescence tumour markers and its implications on survival outcomes of breast cancer patients.

Authors:  Rahmawati Pare; Patsy S Soon; Aashit Shah; Cheok Soon Lee
Journal:  PLoS One       Date:  2019-04-18       Impact factor: 3.240

3.  TROP-2, Nectin-4, GPNMB, and B7-H3 Are Potentially Therapeutic Targets for Anaplastic Thyroid Carcinoma.

Authors:  Soji Toda; Shinya Sato; Nao Saito; Kazumasa Sekihara; Ai Matsui; Daisuke Murayama; Hirotaka Nakayama; Nobuyasu Suganuma; Yoichiro Okubo; Hiroyuki Hayashi; Hiroyuki Iwasaki; Yohei Miyagi; Daisuke Hoshino
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639

4.  Tumor budding and fibrotic focus-proposed grading system for tumor budding in invasive carcinoma no special type of the breast.

Authors:  Miyuki Hiratsuka; Takahiro Hasebe; Toshiaki Saeki; Yuki Ichinose; Ayaka Sakakibara; Akihiro Fujimoto; Noriko Wakui; Satomi Shibasaki; Masataka Hirasaki; Masanori Yasuda; Akemi Nukui; Hiroko Shimada; Hideki Yokogawa; Kazuo Matsuura; Takashi Hojo; Akihiko Osaki
Journal:  Virchows Arch       Date:  2022-06-13       Impact factor: 4.535

5.  Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival.

Authors:  Se Kyung Lee; Soo Youn Bae; Jun Ho Lee; Hyun-Chul Lee; Hawoo Yi; Won Ho Kil; Jeong Eon Lee; Seok Won Kim; Seok Jin Nam
Journal:  PLoS One       Date:  2015-08-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.